GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Accounts Payable & Accrued Expense

Clene (CLNN) Accounts Payable & Accrued Expense : $2.92 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Clene Accounts Payable & Accrued Expense?

Clene's quarterly accounts payable & accrued expense declined from Sep. 2023 ($3.58 Mil) to Dec. 2023 ($3.10 Mil) and declined from Dec. 2023 ($3.10 Mil) to Mar. 2024 ($2.92 Mil).

Clene's annual accounts payable & accrued expense increased from Dec. 2021 ($2.96 Mil) to Dec. 2022 ($4.87 Mil) but then declined from Dec. 2022 ($4.87 Mil) to Dec. 2023 ($3.10 Mil).


Clene Accounts Payable & Accrued Expense Historical Data

The historical data trend for Clene's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Accounts Payable & Accrued Expense Chart

Clene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
3.00 3.72 2.96 4.87 3.10

Clene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 4.11 3.58 3.10 2.92

Clene Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.


Clene (CLNN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Accounts Payable & Accrued Expense
Traded in Other Exchanges
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).
Executives
David J Matlin director
Matthew Kiernan director 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington director, officer: Chief Executive Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Alison Mosca director 26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay director 177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc 10 percent owner 6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman officer: Chief Medical Officer 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown officer: Chief Financial Officer 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson officer: Chief Science Officer 500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz director 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121

Clene (CLNN) Headlines

From GuruFocus

Clene Announces Launch of Proposed Public Offering

By sperokesalga sperokesalga 06-15-2023